Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)

(2015) Olga Ritz et al.   Oncotarget

The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma

(2014) Abraham Avigdor et al.   ANNALS OF HEMATOLOGY

A prospective study of mediastinal gray-zone lymphoma

(2014) W. H. Wilson et al.   BLOOD

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

(2014) David D. W. Twa et al.   BLOOD

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

(2014) Y. Hao et al.   CLINICAL CANCER RESEARCH

Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma

(2014) Jay Gunawardana et al.   NATURE GENETICS

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

(2013) Jacob D. Soumerai et al.   LEUKEMIA & LYMPHOMA

Therapy in Primary Mediastinal B-Cell Lymphoma

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

(2013) Kieron Dunleavy et al.   NEW ENGLAND JOURNAL OF MEDICINE

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

(2012) R. A. de Claro et al.   CLINICAL CANCER RESEARCH

Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?

(2012) Kieron Dunleavy et al.   Current Hematologic Malignancy Reports

Sobering realities of surviving Hodgkin Lymphoma

(2011) K. Dunleavy et al.   BLOOD

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma

(2011) F. C. Eberle et al.   HAEMATOLOGICA

Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations

(2011) Franziska C Eberle et al.   MODERN PATHOLOGY

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

(2010) M. Rieger et al.   ANNALS OF ONCOLOGY

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

(2010) S. M. Castellino et al.   BLOOD

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

(2010) Lixin Rui et al.   CANCER CELL

Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy

(2010) Maureen M. O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

The Value of CD23 Expression as an Additional Marker in Distinguishing Mediastinal (Thymic) Large B-Cell Lymphoma From Hodgkin Lymphoma

(2009) Mohamed E. Salama et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers

(2008) Wyndham H. Wilson et al.   JOURNAL OF CLINICAL ONCOLOGY